These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Chronic inflammatory demyelinating polyradiculoneuropathy in patients with liver transplantation. Echaniz-Laguna A; Battaglia F; Ellero B; Mohr M; Jaeck D Muscle Nerve; 2004 Oct; 30(4):501-4. PubMed ID: 15372442 [TBL] [Abstract][Full Text] [Related]
7. Immunoglobulin replacement therapy in antibody deficiency syndromes: are we really doing enough? Baumann U; Miescher S; Vonarburg C Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):83-5. PubMed ID: 25546772 [No Abstract] [Full Text] [Related]
8. Subcutaneous immunoglobulin therapy for inflammatory neuropathy: current evidence base and future prospects. Rajabally YA J Neurol Neurosurg Psychiatry; 2014 Jun; 85(6):631-7. PubMed ID: 24124042 [TBL] [Abstract][Full Text] [Related]
9. Safety and availability of immunoglobulin replacement therapy in relation to potentially transmissable agents. IUIS Committee on Primary Immunodeficiency Disease. International Union of Immunological Societies. Chapel HM Clin Exp Immunol; 1999 Oct; 118 Suppl 1(Suppl 1):29-34. PubMed ID: 10540201 [No Abstract] [Full Text] [Related]
10. Guidelines for the use of human immunoglobulin therapy in patients with primary immunodeficiencies in Latin America. Condino-Neto A; Costa-Carvalho BT; Grumach AS; King A; Bezrodnik L; Oleastro M; Leiva L; Porras O; Espinosa-Rosales FJ; Franco JL; Sorensen RU Allergol Immunopathol (Madr); 2014; 42(3):245-60. PubMed ID: 23333411 [TBL] [Abstract][Full Text] [Related]
11. Subcutaneous immunoglobulin therapy home. Ozerovitch L Nurs Times; 2013 Dec 11-2014 Jan 14; 109(49-50):20-2. PubMed ID: 24568017 [TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study. Hartung HP; Mallick R; Bril V; Lewis RA; Sobue G; Lawo JP; Mielke O; Durn BL; Cornblath DR; Merkies ISJ; van Schaik IN; Eur J Neurol; 2020 Jan; 27(1):196-203. PubMed ID: 31400231 [TBL] [Abstract][Full Text] [Related]
13. Estimation of the latent therapeutic demand for immunoglobulin therapies in autoimmune neuropathies in the United States. Farrugia A; Bansal M; Marjanovic I Vox Sang; 2022 Feb; 117(2):208-219. PubMed ID: 34110626 [TBL] [Abstract][Full Text] [Related]
14. The ratio of mean daily IgG increment/mean daily dose in immunoglobulin replacement therapy in primary antibody deficiencies. Lucas M; Lee M; Oksenhendler E; Chapel H J Allergy Clin Immunol Pract; 2015; 3(6):998-1000.e2. PubMed ID: 26246125 [No Abstract] [Full Text] [Related]
16. Managing patients with side effects and adverse events to immunoglobulin therapy. Azizi G; Abolhassani H; Asgardoon MH; Shaghaghi S; Negahdari B; Mohammadi J; Rezaei N; Aghamohammadi A Expert Rev Clin Pharmacol; 2016; 9(1):91-102. PubMed ID: 26496172 [TBL] [Abstract][Full Text] [Related]
17. History of immunoglobulin replacement. Eibl MM Immunol Allergy Clin North Am; 2008 Nov; 28(4):737-64, viii. PubMed ID: 18940572 [TBL] [Abstract][Full Text] [Related]
18. New insights into the management of chronic inflammatory demyelinating polyradiculoneuropathy. Rajabally YA; Blomkwist-Markens PH; Katzberg HD Neurodegener Dis Manag; 2015; 5(3):257-68. PubMed ID: 26107324 [TBL] [Abstract][Full Text] [Related]